AI Article Synopsis
- Omicron BA.4 and BA.5 variants of SARS-CoV-2 are highly transmissible and can evade immunity from natural infection and vaccines.
- A study tested 482 human monoclonal antibodies from individuals who received mRNA vaccines either after two or three doses or post-infection, finding that only about 15% could neutralize these variants.
- The research revealed distinct immune responses based on vaccination and infection, suggesting that understanding these differences could lead to better vaccines and treatments for COVID-19 in the future.
Article Abstract
Severe acute respiratory syndrome 2 Omicron BA.4 and BA.5 are characterized by high transmissibility and ability to escape natural and vaccine induced immunity. Here we test the neutralizing activity of 482 human monoclonal antibodies isolated from people who received two or three mRNA vaccine doses or from people vaccinated after infection. The BA.4 and BA.5 variants are neutralized only by approximately 15% of antibodies. Remarkably, the antibodies isolated after three vaccine doses target mainly the receptor binding domain Class 1/2, while antibodies isolated after infection recognize mostly the receptor binding domain Class 3 epitope region and the N-terminal domain. Different B cell germlines are used by the analyzed cohorts. The observation that mRNA vaccination and hybrid immunity elicit a different immunity against the same antigen is intriguing and its understanding may help to design the next generation of therapeutics and vaccines against coronavirus disease 2019.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044118 | PMC |
| http://dx.doi.org/10.1038/s41467-023-37422-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!